New test could help doctors see how brain tumors respond to therapy
NCT ID NCT06610682
First seen Dec 29, 2025 · Last updated May 14, 2026 · Updated 18 times
Summary
This study looks at whether tiny bits of tumor DNA found in blood and spinal fluid can help doctors monitor how well treatment is working in people with a specific type of brain tumor (BRAF-altered glioma). About 24 patients whose cancer has not responded to prior treatments will receive the drug plixorafenib alone or with retifanlimab. The main goal is to see if these DNA levels change with treatment and match what scans show.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600E MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.